Abdera Therapeutics Inc., a biopharmaceutical company leveraging its advanced antibody engineering ROVEr platform to design and develop tunable, precision radiopharmaceuticals for cancer, announced ...
Who are the top ancient Greek philosophers, and what are their contributions to philosophy and modern life? Read on to ...
The next-generation radiopharmaceutical ABD-147 was previously granted FDA fast track designation in extensive-stage small ...
Foscenvivint is under clinical development by Eisai and currently in Phase I for Colorectal Cancer. According to GlobalData, Phase I drugs for Colorectal Cancer have a 75% phase transition success ...
If you're a young person (or a parent of one), you may be thinking some big thoughts about your future. Am I going to go to ...
The US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to Abdera Therapeutics’ ABD-147, a ...
Abdera Therapeutics Inc.’s ABD-147 has been granted U.S. orphan drug designation for the treatment of neuroendocrine carcinoma. ABD-147 is a next-generation precision radiopharmaceutical biologic ...
Abdera Therapeutics Inc., a biopharmaceutical company leveraging its advanced antibody engineering ROVEr™ platform to design and develop tunable, precision radiopharmaceuticals for cancer, today ...
Abdera Therapeutics Inc., a biopharmaceutical company leveraging its advanced antibody engineering ROVErtm platform to design and develop tunable, precision radiopharmaceuticals for cancer ...
SOUTH SAN FRANCISCO--(BUSINESS WIRE)--Abdera Therapeutics Inc., a biopharmaceutical company leveraging its advanced antibody engineering ROVEr™ platform to design and develop tunable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback